Vacant Director

The main objective of CNIO Biobank is to facilitate access and distribution of human samples, ensuring that both the acquisition, maintenance and use complies with all the legal and ethical principles that protect donors’ rights. In this sense, a number of services are implemented, both for sample processing and for supporting different aspects of the management of collections and research projects.

Additionally, CNIO Biobank has its own R&D line and participates in several multicentric Biospecimen Science research projects.

The CNIO Biobank has been instrumental in the origin of collaborative biobanking modelling. In 2001 created the first collaborative network in Europe the CNIO Tumor Bank Network that sparked the development of international networks and European ESFRI in biobanking, BBMRI-ERIC . CNIO biobank has been the coordination node of the Spanish Biobank Network from its origins back in 2009 till 2018, an initiative of the Spanish Research Council, Instituto de Salud Carlos III, ISCIII.

Internationally, CNIO biobank leads and participates in numerous national and international forums, working groups and scientific societies. These include the presidency of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB), Delegate at the International Society for Biological and Environmental Repositories (ISBER), international think tanks such as Marble Arch International Working Group on Clinical Biobanking, BC-Net IARC- WHO/NCI initiative, to name a few.

Publications

• Zagorac I, Fernandez-Gaitero S, Penning R, Post H, Bueno MJ, Mouron S, Manso L, Morente MM, Alonso S, Serra V, Muñoz J, Gómez-López G, Lopez-Acosta JF, Jimenez-Renard V, Gris-Oliver A, Al-Shahrour F, Piñeiro-Yañez E, Montoya-Suarez JL, Apala JV, Moreno-Torres A, Colomer R, Dopazo A, Heck AJR, Altelaar M, Quintela-Fandino M (2018). In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nat Commun 9, 3501.
• Doucet M, Becker KF, Björkman J, Bonnet J, Clément B, Daidone MG, Duyckaerts C, Erb G, Haslacher H, Hofman P, Huppertz B, Junot C, Lundeberg J, Metspalu A, Lavitrano M, Litton JE, Moore HM, Morente M, Naimi BY, Oelmueller U, Ollier B, Parodi B, Ruan L, Stanta G, Turano P, Vaught J, Watson P, Wichmann HE, Yuille M, Zaomi M, Zatloukal K, Dagher G (2017). Quality Matters: 2016 Annual Conference of the National Infrastructures for Biobanking.. Biopreservation & Biobanking 15, 270-276.
• Manso L, Mourón S, Tress M, Gómez-López G, Morente M, Ciruelos E, Rubio-Camarillo M, Rodriguez-Peralto JL, Pujana MA, Pisano DG, Quintela-Fandino M (2016). Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.. PLoS ONE 11, e0155840.
• García-Donas J, Beuselinck B, Inglada-Pérez L, Graña O, Schöffski P, Wozniak A, Bechter O, Apellániz-Ruiz M, Leandro-García LJ, Esteban E, Castellano DE, González Del Alba A, Climent MA, Hernando S, Arranz JA, Morente M, Pisano DG, Robledo M, Rodriguez-Antona C. (2016). Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.. JCI Insight 7, e86051.
• Suárez AE, Artiga MJ, Santonja C, Montes-Moreno S, De Pablo P, Requena L, Piris MA, Rodríguez-Pinilla SM (2016). Angioimmunoblastic T-cell lymphoma with a clonal plasma cell proliferation that underwent immunoglobulin isotype switch in the skin, coinciding with cutaneous disease progression.. J Cutan Pathol 43, 1203-1210.
• Doucet M, Becker KF, Björkman J, Bonnet J, Clément B, Daidone MG, Duyckaerts C, Erb G, Haslacher H, Hofman P, Huppertz B, Junot C, Lundeberg J, Metspalu A, Lavitrano M, Litton JE, Moore H, Morente M, Naimi BY, Oelmueller U, Ollier B, Parodi B, Ruan L, Stanta G, Turano P, Vaught J, Watson P, Wichmann HE, Yuille M, Zaomi M, Zatloukal K, Dagher G (2016). Annual Conference of the National Infrastructures for Biobanking. Biopreservation & Biobanking (in press).
• Thomsen MK, Bakiri L, Hasenfuss SC, Wu H, Morente M, Wagner EF. (2015). Loss of JUNB/AP-1 promotes invasive prostate cancer.. Cell Death Differ 22, 574-582.
• Riegman PH, de Jong B, Daidone MG, Söderström T, Thompson J, Hall JA, Mendy M, Ten Hoeve J, Broeks A, Reed W, Morente MM, López-Guerrero JA, Collins VP, Rogan J, Ringborg U (2015). Optimizing sharing of hospital biobank samples.. Sci Transl Med 7, fs31.
• Zapatero A, Morente M, de Vidales CM, Adrados M, Lopez C, Nieto S, González MJ, Arellano R, Conde AC, Vicente FG. (2015). HIF1A expression in localized prostate cancer treated with dose escalation radiation therapy.. Cancer Biomark 1, 41-46.
• Zapatero A, Morente M, Nieto S, Martín de Vidales C, Lopez C, Adrados M, Arellano R, Artiga MJ, Garcia-Vicente F, Herranz LM, Leaman O (2014). Predictive value of PAK6 and PSMB4 expression in patients with localized prostate cancer treated with dose-escalation radiation therapy and androgen deprivation therapy.. Urol Oncol-Semin Ori 32, 1327-1332.
• Odqvist L, Sánchez-Beato M, Montes-Moreno S, Martín-Sánchez E, Pajares R, Sánchez-Verde L, Ortiz-Romero PL, Rodriguez J, Rodríguez-Pinilla SM, Iniesta-Martínez F, Solera-Arroyo JC, Ramos-Asensio R, Flores T, Palanca JM, Bragado FG, Franjo PD, Piris MA. (2013). NIK Controls Classical and Alternative NF-?B Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells.. Clin Cancer Res 19, 2319-2330.
• Pros E, Lantuejoul S, Sanchez-Verde L, Castillo SD, Bonastre E, Suarez-Gauthier A, Conde E, Cigudosa JC, Lopez-Rios F, Torres-Lanzas J, Castellví J, Ramon y Cajal S, Brambilla E, Sanchez-Cespedes M. (2013). Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.. Int J Cancer 133, 898-907.
• Garcia-Donas J, Leandro-García LJ, González Del Alba A, Morente M, Alemany I, Esteban E, Arranz JA, Climent MA, Gallardo E, Castellano DE, Bellmunt J, Mellado B, Puente J, Moreno F, Font A, Hernando S, Robledo M, Rodríguez-Antona C. (2013). Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.. Ann Oncol 24, 2409-2414.
• Montes-Moreno S, Ramos-Medina R, Martínez-López A, Barrionuevo Cornejo C, Parra Cubillos A, Quintana-Truyenque S, Rodriguez Pinilla SM, Pajares R, Sanchez-Verde L, Martinez-Torrecuadrada J, Roncador G, Piris MA (2013). SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms.. Blood 121, 643-647.
• Monsálvez V, Montes-Moreno S, Artiga MJ, Rodríguez ME, Espiridión BS, Lozano M, Fernández-de-Misa R, Rodríguez-Peralto JL, Piris MA, Ortíz-Romero PL (2013). MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma.. Mod Pathol 26, 617.
• Martinez-Lopez A, Montes-Moreno S, Mazorra F, Miranda-Vallina C, Ulibarrena C, Martin JL, Bosch JM, Peri V, Burdaspal A, Fernandez-Alvarez M, Sanchez-Verde L, Piris MA (2013). Persistent polyclonal B-cell lymphocytosis with splenomegaly: histologic description of 2 cases.. Am J Surg Pathol 37, 1085-1090.
• Rodríguez-Pinilla SM, Ortiz-Romero PL, Monsalvez V, Tomás IE, Almagro M, Sevilla A, Camacho G, Longo MI, Pulpillo Á, Diaz-Pérez JA, Montes-Moreno S, Castro Y, Echevarría B, Trébol I, Gonzalez C, Sánchez L, Otín AP, Requena L, Rodríguez-Peralto JL, Cerroni L, Piris MÁ. (2013). TCR-? expression in primary cutaneous T-cell lymphomas.. Am J Surg Pathol 37, 375-384.
• Moya P, Esteban S, Fernandez-Suarez A, Maestro M, Morente M, Sánchez-Carbayo M (2013). KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer.. Tumor Biol 34, 471-479.
• Gonzalez Sanchez BM, Lopez-Valeiras E, Morente MM, Fernández Lago O (2013). Cost Model for Biobanks.. Biopreservation & Biobanking 272, 277.

Biobank

CNIO Biobank (authorised by the Comunidad Autónoma de Madrid Health Department and registered in the National Registry of Biobanks with reference B.000848) is a ‘biobank for biomedical research purposes’, as defined by the Spanish Law 14/2007 and the Royal Decree RD 1716/2011. It´s therefore defined as a public, non-profit organization that hosts several human sample collections for biomedical research following quality and order criteria.